Endovascular Engineering Unveils Groundbreaking Research at SIR and SCAI 2026 Conferences Endovascular Engineering, Inc. announces acceptance of two significant abstracts for SIR and SCAI 2026, showcasing advancements in thrombectomy for pulmonary embolism.

Endovascular Engineering Unveils Groundbreaking Research at SIR and SCAI 2026 Conferences #United_States #Menlo_Park #Endovascular_Engineering #ENGULF_Study #Hēlo_Platform

E2 Appoints Justin Farry as CFO to Enhance Financial Strategy and Growth Endovascular Engineering, Inc. has appointed Justin Farry as Chief Financial Officer. His expertise will be key for growth and commercialization of new medical technologies.

E2 Appoints Justin Farry as CFO to Enhance Financial Strategy and Growth #USA #Menlo_Park #Endovascular_Engineering #Thrombectomy_System #Justin_Farry

E2 Completes Enrollment for Revolutionary Pulmonary Embolism Treatment Study E2 completes patient enrollment in the pivotal ENGULF study for its Hēlo™ PE Thrombectomy System, aimed at treating life-threatening pulmonary embolism.

E2 Completes Enrollment for Revolutionary Pulmonary Embolism Treatment Study #USA #Menlo_Park #Endovascular_Engineering #Hēlo_Thrombectomy #Pulmonary_Embolism

Endovascular Engineering Secures $42 Million to Revolutionize Pulmonary Embolism Treatment Endovascular Engineering has successfully raised $42 million in funding to enhance its innovative technology aimed at treating pulmonary embolism, supporting groundbreaking advancements in healthcare.

Endovascular Engineering Secures $42 Million to Revolutionize Pulmonary Embolism Treatment #United_States #Menlo_Park,_California #Endovascular_Engineering #Hēlo_Thrombectomy #Pulmonary_Embolism